Producer
Civica Rx
Non-profit generic drug company founded by hospital systems. Launched insulin glargine biosimilar at $45/box of 5 pens (January 2026) — 85–90% below Big Three list prices. Fill-finish facility in Petersburg, VA. Drug substance supplied by Biocon. First national non-oligopoly insulin supplier in the US.
0
Inputs supplied
0
Goods downstream
1
Facilities
0
Stories
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Critical Hospital Generic Injectables
75%Biosimilar Insulin (CivicaScript)
15%Manufacturing Infrastructure
10%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2025
Civica Rx is publicly known as a hospital drug nonprofit addressing IV drug shortages, but their January 2026 biosimilar insulin launch represents the first serious structural disruption to the US insulin pricing oligopoly in the drug's century of commercial history. Insulin has been sold in the US since 1923. For nearly all of that time, three companies (Novo Nordisk, Eli Lilly, Sanofi) have controlled the US market and priced insulin at $200-$400/vial list price while identical molecules sell for $10-$30 in Canada and Europe. Civica sources drug substance from Biocon (India), performs fill-finish at Petersburg, Virginia, and sells through Mark Cuban's Cost Plus Drugs at $35/vial — the same active ingredient at 90% lower cost. The hospital systems that created Civica to fix IV antibiotic shortages have inadvertently built the manufacturing infrastructure to challenge insulin pricing — a consumer out-of-pocket drug cost that kills approximately 1,200 Americans per year who ration doses due to cost. Hospital supply chain policy created a consumer drug pricing reform tool.
Civica Rx ↗Origin2023
Civica Rx is a nonprofit generic drug company — an institutional structure with no precedent in US pharmaceutical manufacturing. It was founded in 2018 by seven major US hospital systems (Mayo Clinic, Intermountain Healthcare, Ascension, Providence, SSM Health, Trinity Health, and CommonSpirit Health) after the 2010-2018 generic injectable shortage crisis left hospitals unable to obtain drugs like sodium bicarbonate, atropine, and vasopressors during emergencies. The founding insight: the generic injectable market fails because manufacturers exit when margins compress, creating shortages in exactly the drugs (cheap commodities) that hospital patients need most. A nonprofit with hospital-system shareholders has no reason to exit low-margin essential drugs. Civica Rx now supplies ~1,500 hospital members representing approximately 55% of US hospital beds, and manufactures critical generics at a Petersburg, Virginia fill-finish facility. When it launched biosimilar insulin in January 2026 at $45/box — financed by the Arnold Foundation and using Biocon drug substance — it became the first structural challenger to the Novo Nordisk/Eli Lilly/Sanofi insulin pricing cartel in US history. A nonprofit hospital consortium accidentally became a pharmaceutical manufacturer.
Civica Rx ↗Substitution2025
Civica Rx, a non-profit founded by hospital systems, launched insulin glargine biosimilar pens at $45/box of 5 (January 2026) — 85–90% below Big Three list prices. Drug substance is supplied by India's Biocon and fill-finished at Civica's Petersburg, VA facility. This marks the first national US competitor to the insulin oligopoly not relying on PBM rebate negotiations.
Civica Rx ↗